Geneoscopy
Saint Louis
About Geneoscopy
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently, there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasive colonoscopy. Geneoscopy is changing that. It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $217.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2025)
- Website: geneoscopy.com
- Phone: 314-887-7777
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/geneoscopy-4839 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.